European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
                    
                    
                
                created: Sept. 22, 2025, 8:30 a.m. | updated: Sept. 23, 2025, 7:46 a.m.
                    Advanz Pharma is responsible for registration and has exclusive rights for commercialization in Europe.
Alvotech Forward-Looking StatementsCertain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made.
Advanz Pharma Forward-Looking StatementsCertain statements in this press release are forward-looking statements.
You should not place undue reliance on forward-looking statements, which speak of the date of this press release.
                    
                
                
                1 month, 1 week ago: News Ticker - markets.businessinsider.com